Jemperli contends with blockbuster Keytruda in endometrial cancer [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
with standard of care (SOC) chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp)/microsatellite stable (MSS) status, which is a severely underserved patient population. The sBLA approval is based on the success of the Phase III RUBY Part I trial and places Jemperli in direct competition with Merck & Co's Keytruda (pembrolizumab), the blockbuster agent of the same immune checkpoint inhibitor (ICI) class. Jemperli is a monoclonal antibody targeting PD-1, an inhibitory immunological checkpoint receptor, which activates an anti-tumor immune response during cancer treatment. Jemperli has already been approved in combination with SOC chemotherapy, followed by Jemperli as monotherapy, for the treatment of recurrent or advanced endometrial cancer adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) status. In the Phase III RUBY Part I trial, the
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- XtalPi to Host Inaugural Symposium on the Acceleration of Drug Discovery Through the Use of AI, Automation, and Digitalization [Yahoo! Finance]Yahoo! Finance
- Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation [Yahoo! Finance]Yahoo! Finance
- Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline [Yahoo! Finance]Yahoo! Finance
- Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse PipelineBusiness Wire
- Global Oxytocin Market Forecasts Substantial Growth Through 2029 Amid Increased Focus on Maternal Health and Innovative Medical Applications [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 5/15/24 - Form 424B5
- 5/15/24 - Form POSASR
- 5/6/24 - Form 144
- MRK's page on the SEC website